Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed January 24, 2022.
   Google Scholar
• Volgelmeir CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:1533. doi:10.12688/f1000research.19811.1
   Google Scholar
• Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:469–479. doi:10.2147/COPD.S48492
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS/LABA therapy, a meta-analysis of triple combination therapy in COPD. Chest. 2019;155:758–770. doi:10.1016/j.chest.2018.12.016
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210–223. doi:10.1016/S2213-2600(13)70040-7
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12:27–34. doi:10.1513/AnnalsATS.201409-413OC
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: arctic an observational study. Resp Research. 2018;19:172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernest P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036. doi:10.1136/thoraxjnl-2012-202872
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Rigby A, Morice AH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT Study. Lung. 2017;195:281–288. doi:10.1007/s00408-017-9990-8
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. doi:10.1136/bmj.f3306
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li S, Zhou W, Yang X, Li J, Cao J. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020;17:462–469. doi:10.1080/15412555.2020.1787369
   PubMedGoogle Scholar
• Sonnappa S, Martin R, Israel E, et al. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017;12:e0178112. doi:10.1371/journal.pone.0178112
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Solidoro P, Patrucco F, Bagnasco D. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta agonist combinations in patients with chronic obstructive pulmonary disease: a review. Expert Rev Respir Med. 2019;13:1087–1094. doi:10.1080/17476348.2019.1665514
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–1929. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al.; for the FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Resp Med. 2014;108:1153–1162. doi:10.1016/j.rmed.2014.05.013
   PubMed Web of Science ®Google Scholar
• Hillyer EV, Price DB, Chrystyn H, et al.; Roche N on behalf of the Respiratory Effectiveness Group, Small Airways Study Group. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31:1–3. doi:10.1089/jamp.2017.1396
   PubMed Web of Science ®Google Scholar
• Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1–28. doi:10.1177/1753466619884532
   Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137–148. doi:10.1089/jamp.2009.0772
   PubMed Web of Science ®Google Scholar
• Usmani OS, Mignot B, Kendall I, et al. Predicting lung deposition of extrafine inhaled corticosteroid-containing fixed combination in patients with chronic obstructive pulmonary disease using functional respiratory imaging: an in silico study. J Aerosol Med Pulm Drug Deliv. 2021;34:204–211. doi:10.1089/jamp.2020.1601
   PubMed Web of Science ®Google Scholar
• Collice G, Chisholm A, Dima AL, et al. Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Pragmat Obs Res. 2018;9:29–42. doi:10.2147/POR.S151615
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2020. Available from: https://www.R-project.org/. Accessed January 24, 2022.
   Google Scholar
• Sekhon JC. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw. 2011;42:1–52. doi:10.18637/jss.v042.i07
   Web of Science ®Google Scholar
• Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186. doi:10.2147/COPD.S68289
   PubMed Web of Science ®Google Scholar
• Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–1050. doi:10.1183/09031936.00074905
   PubMed Web of Science ®Google Scholar
• Hübner M, Hochhaus G, Hartmut D. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25:469–488. doi:10.1016/j.iac.2005.05.004
   PubMed Web of Science ®Google Scholar
• Chang TY, Chien JY, Wu CH, Dong YH, Lin FJ. Comparative safety and effectiveness of inhaled corticosteroid and long-acting β2-agonist combinations in patients with COPD. Chest. 2020;157:1117–1129. doi:10.1016/j.chest.2019.12.006
   PubMed Web of Science ®Google Scholar
• Lipworth B, Kuo CR, Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3003–3009. PMID: 30319248; PMCID: PMC6167973. doi:10.2147/COPD.S177333
   PubMed Web of Science ®Google Scholar
• Jones R, Martin J, Thomas V, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445–2454. doi:10.2147/COPD.S141409
   PubMed Web of Science ®Google Scholar
• Thomsen M, Nordestgaard BG, Vestbo J, Lange P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med. 2013;1:543–550. doi:10.1016/S2213-2600(13)70137-1
   PubMed Web of Science ®Google Scholar